The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 318-323

  Huang, Ke Jin ^a   Sui, Li Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

E cadherin; Metastasis; MMP 2; Ovarian cancer; Prognosis; VEGF C

Indexed keywords

GELATINASE A; UVOMORULIN; VASCULOTROPIN C;

ARTICLE; ASCITES; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84864058435     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9817-4     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. Epub 2010 Jul 7.
2. Aravantinos G, et al. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long term efficacy results: a Hellenic cooperative oncology group (HeCOG) study. Ann Oncol. 2005; 16(7):1116-22. (Pubitemid 41418314)
3. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35. discussion 35-36.
4. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer. 2000;36(13):1621-30. (Pubitemid 30616366)
5. Tester AM, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004;64(2):652-8. (Pubitemid 38120906)
6. Tsung AJ, et al. Downregulation of Matrix Metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model. Int J Oncol. 2008;32(3):557-64. (Pubitemid 351330461)
7. Hirata K, et al. Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis. Oncology. 2006; 71(1-2):102-10. Epub 2007 Mar 6. (Pubitemid 46588169)
8. Tang RF, et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas. 2001;22(3): 285-92. (Pubitemid 32242495)
9. Liang H, et al. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. Int J Biol Markers. 2010;25(1):38-45.
10. Su JL, et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 2007;96(4):541-5. Epub 2006 Dec 12.
11. Fukunaga S, et al. Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology. 2006; 71(3-4):204-11. Epub 2007 Jul 19.
12. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009;69(1):349-57.
13. Huang HY, Ho CC, Huang PH, Hsu SM. Co-expression of VEGF-C and its receptor, VEGFR-2 and VEGFR-3 in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab Invest. 2001;81(12):1729-34.
14. Foster RR, Slater SC, Seckley J. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. Am J Pathol. 2008;173(4):938-48. Epub 2008 Sep 4.
15. Bell J, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2006;102(3):432-9. (Pubitemid 44353663)
16. DuPont NC, Berman ML. Surgical management of epithelial ovarian cancer: a review of the literature. Min Ginecol. 2004; 56(6):547-56. (Pubitemid 43942394)
17. Sakuragi N, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol. 2000;79(2):251-5.
18. Ayhan A, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer. 2007;17(1):68-75. (Pubitemid 46213972)
19. Torng PL, Mao TL, Chan WY. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol. 2004;92(2):559-67.
20. Kamel H, Abdelazim I, Habib SM, El Shourbagy MA, Ahmed NS. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumors. J Obstet Gynaecol Can. 2010;32(6):580-6.
21. Ueda M, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res. 2005;11(9):3225-32. (Pubitemid 40627869)